Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus in metastatic renal cell cancer
NCT00446368Phase 2Completed
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2005
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in renal cell carcinoma (RCC), sponsored by Houston Methodist Research Institute. Primary endpoint: Time to Tumor Progression at 8 weeks. Started May 2005; status: completed.
02
Drugs
everolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00446368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446368.